Vega Therapeutics, Inc.: Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease
Phase 1 clinical trial advances with first subject dosed in the E.U. and IND accepted in the U.S. Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare
Source: finanznachrichten.de